HEART UK - The Cholesterol Charity’s Post

Headlines are again covering a rise in COVID-19 infections. With those of old age and those with comorbidities at higher-risk of developing severe symptoms and requiring hospitalization. Antiviral treatments are a category of drug that, when given after a positive test, can prevent development of severe symptoms and thus hospitalization. I am thrilled to share our latest paper that explores efficacy thresholds and target populations for antiviral COVID-19 treatments to save both lives and costs using our SARS-CoV-2 transmission model. https://lnkd.in/drush8sF We found that, for a sufficiently efficacious antiviral treatment, expanding the target population to include both high-risk and moderate-risk groups should be considered. Equitable treatment costs are found crucial in achieving the best possible public health and health economic outcomes globally. Team work makes the dream work: Andrew Shattock, Inês Marcelino, Sophie Goldenberg, Melissa Penny Swiss Tropical and Public Health Institute, Basel Research Centre for Child Health, Swiss National Science Foundation SNSF, Telethon Kids Institute, The University of Western Australia, Vanderbilt University Medical Center, Vanderbilt University, Faculteit Diergeneeskunde (Universiteit Utrecht), Wageningen University & Research, The Lancet

Thrilled to share my latest research on the recurrence of cardiovascular events after an acute myocardial infarction in patients with multivessel disease! This study investigates the impact of multivessel disease on healthcare costs and patient outcomes utilizing German claims data. In the study, we found that: -Presence of multivessel disease is associated with higher rates of recurrent myocardial infarction. -Patients with multivessel disease had higher rates of recurrent MI despite receiving more guideline-directed medication therapy. -Conversely, there was a higher mortality rate observed in the non-multivessel disease cohort. You can find the paper here: https://lnkd.in/dvxTQuqG #cardiovascular #multivesseldisease #myocardialinfarction #healthcarecosts #patientoutcomes #research

🌟 Insights in Healthcare: New Study Challenges Effectiveness of D-Mannose in UTI Treatment Recent research has shed light on an important aspect of urinary tract infection (UTI) treatment, particularly in the context of D-mannose supplementation. A comprehensive study published in JAMA Internal Medicine has reported findings indicating that D-mannose, a commonly used supplement in UTI medications, may not be significantly more effective than a placebo.This revelation underscores the complexity of managing UTIs and highlights the need for evidence-based approaches in healthcare. While D-mannose has been popularized for its potential benefits in preventing UTIs by preventing bacteria from adhering to the bladder wall, this study suggests that further investigation is required to delineate its true efficacy. As healthcare professionals and researchers, it's imperative that we continue to critically evaluate treatment modalities to ensure optimal patient care. This study invites us to delve deeper into the mechanisms of UTI management and to explore alternative strategies where necessary. Let's use this opportunity to foster discussions around evidence-based medicine and the evolving landscape of UTI treatment. Your thoughts and insights on this topic are invaluable! 💬 #UTI #HealthcareResearch #EvidenceBasedMedicine #Dmannose #UTITreatment #HealthcareInnovation #MedicalResearch #PatientCare #HealthcareProfessionals https://lnkd.in/eYFBempB

Cardio Diagnostics (@cardiodiagnostics), an AI-driven precision cardiovascular medicine company, is anticipating a pivotal decision from the Centers for Medicare and Medicaid Services (CMS) regarding payment determinations for its cutting-edge heart disease tests. In June, the company presented pricing recommendations for its Epi+Gen CHD and PrecisionCHD tests at the CMS annual meeting. These AI-powered solutions aim to revolutionize the prevention, detection, and management of coronary heart disease (CHD), the leading cause of death among Medicare beneficiaries. 'Our cutting-edge tests represent a significant advancement in the prevention, detection and management of coronary heart disease, and we are committed to making them accessible to Medicare beneficiaries,' stated Meesha Dogan, PhD, CEO and Co-Founder of Cardio Diagnostics. The CMS is expected to release its preliminary payment determinations in September, based on the information provided at the annual meeting, public comments, and recommendations from the Clinical Diagnostic Laboratory Tests (CDLT) Advisory Panel. Final determinations are anticipated in November. With the crucial decision looming, Cardio Diagnostics is poised for a breakthrough that could bring its innovative heart disease tests closer to widespread accessibility for Medicare patients, potentially saving millions of lives. #cardiovasculardisease #medicare #precisionmedicine Cardio Diagnostics Inc.

💓 Celebrating World Heart Day with Cyntegrity’s Cardiovascular RACT 💓 As we celebrate World Heart Day on September 29th, we recognize the crucial role clinical research plays in cardiovascular health. 🩺 At Cyntegrity, our indication focused MyRBQM® RACT catalog for cardiovascular diseases helps research teams manage patient safety, ensure accurate enrollment, and reduce drop-out rates in clinical trials. 📊 Our therapy specific RACTs provide tailored solutions for long-term trial success, making risk assessment and management easier and more efficient.🏆 Our RACT (risk register) on cardiovascular diseases, when implemented and used, addresses various aspects of risks related to: 💡Managing the safety of patients suffering from cardiovascular diseases and participating in clinical trials.  ✅ Allowing checking whether the right patient population has been enrolled into the study. ⏳ Providing oversight on timely reaction to any study aspects requiring a rapid response.  🔗For long term studies, keeping the drop out rate and lost to follow up rate under control. 📊Determining whether the study sites are comparable or whether they are delivering extremely different data. Learn more about the challenges of clinical research in heart failure here: 👉 https://lnkd.in/dFWKrW2F Discover how our RACT can streamline your risk management process: 👉 https://lnkd.in/e2tQpG6P #WorldHeartDay #Cyntegrity #CardiovascularHealth #ClinicalTrials #RBQM #RiskManagement #HeartResearch #PatientSafety #MedicalInnovation #HealthcareTransformation #RACT

Sanofi wins seventh indication for Dupixent (dupilumab) for uncontrolled chronic obstructive pulmonary disease (COPD), and sets a new therapy option for approximately 220,000 adults in the EU. The approval is based on results from two landmark phase 3 studies: - BOREAS (https://lnkd.in/e-xm242W) - NOTUS (https://lnkd.in/eHXwk7zr) BOREAS and NOTUS were separately published in The New England Journal of Medicine. Both studies evaluated the efficacy and safety of Dupixent in adults with uncontrolled COPD with evidence of type 2 inflammation. Those who received dupilumab had benefits, like: - Fewer exacerbations - Better lung function - Quality of life - Less severe respiratory symptoms than those who received placebo Kudos to the Sanofi team. Dupixent could hit $20B in peak sales with COPD expansion!

VICTORION-INITIATE trial An “Inclisiran first” implementation strategy led to greater LDL-C lowering compared with usual care without discouraging statin use or raising new safety concerns. The use of more powerful lipid lowering therapies to control LDLc early on can help physicians achieve lower levels and reduce CV mortality. The "step-wise" approach has shown lower efficacy in other diseases such as HTN & DM; it's time to be more aggressive in those patients with high and very high risk patients. https://lnkd.in/eWXr-ftM

Data indicates that patients who do not meet LDL-C goals have a nearly 50% higher risk of cardiovascular events.2 Additionally, up to 80% of patients with ASCVD remain on the same statin regimen despite having LDL-C of 70 mg/dL or higher, and patients who did achieve their LDL-C goals only maintained it for an average of 6 months.3 Furthermore, in a survey of attendees at the AHA session, respondents said patients adhere to their lipid-lowering therapy for a relatively short period, with 44% saying 6 months or less.1

JIM│ Glucocorticoid therapy for acute respiratory distress syndrome: Current concepts Link: https://buff.ly/3WWIDo0 #ARDS #Glucocorticoids #Steroids #COVID-19 #Clinical trials #Heterogeneity Yuanrui Zhao, Zhun Yao, Song Xu, Lan Yao, Zhui Yu Acute respiratory distress syndrome (ARDS) represents a major global public health burden. There remains no confirmed specific pharmacotherapy for ARDS, despite advances in understanding its pathophysiology. Debate continues about the potential role of glucocorticoids (GCs) as a promising ARDS clinical therapy, with questions regarding GCs agent, dose, and duration in ARDS patients need to be answered. Substantial variations in GCs administration regimens across studies, and ARDS heterogeneity likely affects the therapeutic actions of exogenous GCs. This review highlights the mechanisms of GCs in ARDS on the basis of ARDS pathophysiology. In addition, we discuss the influence of heterogeneity of ARDS on GCs therapy. Moreover, we also discuss several aspects, including intervention stage, mortality, the dose/duration as well as side effects of GCs therapy in ARDS. Representative randomized controlled trials of ARDS on GCs therapy are also provided.

The EMPA-REG trial investigated the effects of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, on cardiovascular and renal outcomes. The results were groundbreaking: ✅ Significant reduction in cardiovascular death : Empagliflozin demonstrated a 38% reduction in cardiovascular death among patients with type 2 diabetes and established cardiovascular disease. ✅ Reduced hospitalization for heart failure : There was a 35% reduction in the risk of hospitalization for heart failure. ✅ Renal benefits : The trial also showed a 39% reduction in the progression of kidney disease, highlighting the renal protective effects of empagliflozin. These findings underscore the critical role of SGLT2 inhibitors in not only managing blood glucose levels but also in providing substantial cardiovascular and renal protection. The EMPA-REG trial has paved the way for new treatment paradigms that prioritize the overall health and well-being of patients with type 2 diabetes. #CardiovascularHealth #RenalHealth #Type2Diabetes #ClinicalTrials #EMPAREG #SGLT2Inhibitors #HealthcareInnovation #PatientCare